Skip to content

Released Jun 29, 2022, after the close

10-K filed Jun 29, 2022, 90 days after period end · 0001493152-22-018108

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$7.67Mderived+74.5% vs Q4 2021−14.5% vs Q3 2022
Net Income$2.43MderivedN/M vs Q4 2021+6.4% vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$3,456,014+85.2%
Operating Incomederived$851,675N/M
Operating Cash Flowderived$1,605,336N/M
Margins · derived
Gross margin45.0%+2.6 pt vs Q4 2021
Operating margin11.1%+35.4 pt vs Q4 2021
Net margin31.7%+42.6 pt vs Q4 2021

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019derived from reported figures
Revenue$7.67M$4.40M$4.95M$1.34M
Net Income$2.43M-$482.62K$936.37K-$2.66M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Elite Pharmaceuticals Inc · CIK 1053369 · Engraved from SEC EDGAR